Patents

Patent covers therapeutic use of VEGFR antibody with radiation or chemotherapy

Published in Cancer Weekly, December 28th, 2004

ImClone Systems Incorporated (IMCL) announced that the company has received U.S. Patent No. 6,811,779 from the U.S. Patent and Trademark Office covering the therapeutic use of a vascular endothelial growth factor receptor (VEGFR) antibody and either radiation or a chemotherapeutic agent for use in the treatment of cancer.

ImClone Systems is developing two investigational antibodies, IMC-18F1 and IMC-1121B, designed to target two forms of VEGFR.

IMC-1121B is a fully human monoclonal antibody that is designed to bind to the vascular endothelial growth factor receptor-2 (VEGFR-2 or KDR) found on tumor vasculature, thereby inhibiting certain ligands...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-12-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry